On the reading of the bill, it is possible that the director-general, in giving a notification under these provisions, could provide for vaccination to be available to those currently not covered by approvals of Pharmac or Medsafe, but in order to do so, the director-general has to have access to relevant data and has to be sure about the safety and therapeutic benefit of doing so. That's what clause 4 largely takes us to. 